Grufity logoGrufity logo

VERU

5.50USD+0.02(+0.36%)Market Closed

Veru Inc

Market Summary

USD5.50+0.02Market Closed
0.36%

VERU Stock Price

RSI Chart

Valuation

Market Cap

978.6M

Price/Earnings

-20.8

Price/Sales

18.67

Price/Cashflow

-35.67

MarketCap/EBT

-20.74

Price/Sales

Profitability

EBT Margin

-90.02%

Return on Equity

-40.26%

Return on Assets

-29.3%

Fundamentals

Revenue

Revenue (TTM)

52.4M

Revenue Y/Y

-45.61%

Revenue Q/Q

-26.3%

Earnings

Earnings (TTM)

-47.0M

Earnings Y/Y

-724.24%

Earnings Q/Q

-56.55%

Price Action

52 Week Range

4.3424.55
(Low)(High)

Last 7 days

-2.0%

Last 30 days

-52.0%

Last 90 days

-62.8%

Trailing 12 Months

-20.9%

Financial Health

Current Ratio

4.62

Investor Care

Shares Dilution (1Y)

0.37%

Diluted EPS (TTM)

-0.59

Peers (Alternatives to Veru)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
320.4B
80.5B
13.29% 4.81%
21.99
3.98
4.31% 3.03%
72.2B
17.3B
25.82% -28.26%
29.98
4.07
1.35% -16.24%
62.3B
17.7B
7.42% 6.07%
32.33
3.51
2.30% -27.65%
18.6B
5.3B
15.03% -7.68%
25.18
3.49
3.74% -10.11%
18.2B
7.0B
9.44% -6.65%
39.49
2.57
-2.63% -7.32%
MID-CAP
5.6B
5.3B
25.70% -16.55%
21.76
1.06
9.13% 182.41%
2.6B
986.6M
25.68% 9.75%
25.86
2.67
15.68% -0.25%
2.3B
5.3B
0.74% -52.98%
6.82
0.42
-9.40% -36.81%
2.3B
417.7M
32.65% 79.12%
82.15
5.5
19.13% 115.17%
2.0B
2.5B
14.93% -3.88%
17.83
0.82
-12.44% -52.04%
SMALL-CAP
1.1B
1.0B
6.72% -45.35%
11.88
0.98
-15.59% -43.40%
978.6M
52.4M
-52.01% -20.86%
-20.8
18.67
-8.63% -32642.41%
173.8M
447.3M
3.34% -49.50%
10.09
0.39
8.21% -28.15%
49.5M
204.9M
1.06% -40.96%
15.85
0.24
-6.25% -96.99%
10.4M
11.0M
-2.25% -82.47%
-0.47
0.91
127.87% -51.02%

Financials for Veru

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue-13.3%5260616157
Gross Profit-13.8%4249494845
Operating Expenses17.2%8371605346
  S&GA Expenses20.3%3126232118
  R&D Expenses15.4%5245373328
Earnings Before Taxes-53.7%-47.18-30.69-19.314-4.03
Net Income-70.8%-47.05-27.55-16.217-0.14
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-7.1%161173172178180
  Current Assets-8.6%128140146152154
  Inventory20.4%86567
  Net PPE5.5%11110
  Goodwill0%77777
Liabilities18.7%4437242625
  Current Liabilities31.3%2821141617
Shareholder's Equity-14.1%117136148152155
  Retained Earnings-21.7%-124.55-102.36-88.18-81.80-77.50
  Additional Paid-In Capital1.2%249246244242240
Shares Outstanding0.1%8080808080
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-4.5%-27.43-26.25-24.89-15.57-15.11
  Share Based Compensation13.9%87654
Cashflow From Investing154.5%4221515
Cashflow From Financing1115.3%1-0.06108110108

Risks

What is the probability of a big loss on VERU?

100%


Probability that Veru stock will be more than 20% underwater in next one year

88.8%


Probability that Veru stock will be more than 30% underwater in next one year.

86.5%


Probability that Veru stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VERU drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Veru was unfortunately bought at previous high price.

Returns

Cumulative Returns on VERU

-2.2%


10-Year Cumulative Returns

19.8%


7-Year Cumulative Returns

39%


5-Year Cumulative Returns

35.9%


3-Year Cumulative Returns

What are the long-term rolling returns for VERU?

FIve years rolling returns for Veru.

Which funds bought or sold VERU recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
554,000
554,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.82
1,000
931,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-29,000
-
-%
2022-11-15
MERCER GLOBAL ADVISORS INC /ADV
ADDED
36.68
51,000
180,000
-%
2022-11-15
OLIVER LAGORE VANVALIN INVESTMENT GROUP
UNCHANGED
-
-
2,000
-%
2022-11-15
STATE STREET CORP
ADDED
2.33
595,000
14,362,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
105.04
214,309
410,861
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
Northeast Financial Consultants Inc
NEW
-
187,000
187,000
0.01%
2022-11-15
JANE STREET GROUP, LLC
NEW
-
1,852,000
1,852,000
-%

1–10 of 33

Latest Funds Activity

Are funds buying VERU calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own VERU

Veru News

Nasdaq

Pre-Market Earnings Report for December 5, 2022 : SAIC, VERU, DLHC.24 hours ago

The Motley Fool

Is Veru a Buy?.31 hours ago

The Motley Fool

VERU Fair Value

Recent SEC filings of Veru

View All Filings
Date Filed Form Type Document
Nov 14, 2022
SC 13G/A
Major Ownership Report
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading

Latest Insider Trading transactions for VERU

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-15
Eisenberger Mario
ACQUIRED
156,950
1.5695
100,000
-
2022-08-15
Eisenberger Mario
SOLD
-2,003,550
20.0355
-100,000
-
2021-08-17
Lu Lucy
BOUGHT
32,542.1
6.7796
4,800
-
2021-06-16
FISCH HARRY
SOLD
-835,300
8.353
-100,000
-
2021-03-10
Hyun Grace
BOUGHT
49,315
14.09
3,500
-
2021-02-12
STEINER MITCHELL SHUSTER
SOLD
-417,688
20.8844
-20,000
President and CEO
2020-12-16
BARNETTE K GARY
SOLD
-1,064,510
10.6451
-100,000
Chief Scientific Officer
2020-12-16
STEINER MITCHELL SHUSTER
SOLD
-2,421,620
9.6865
-250,000
President and CEO
2020-08-26
FISCH HARRY
BOUGHT
13,799.5
2.7599
5,000
-
2020-08-24
Greco Michele
BOUGHT
13,233
2.6466
5,000
CAO and CFO

1–10 of 50

Mitchell S. Steiner
250
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Income Statement

2022-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]    
Net revenues$ 9,602,195$ 17,655,592$ 36,765,721$ 45,613,068
Cost of sales2,533,5723,782,4806,679,7389,995,023
Gross profit7,068,62313,873,11230,085,98335,618,045
Operating expenses:    
Research and development18,133,41211,188,24643,755,67724,438,813
Selling, general and administrative10,758,9865,556,73024,881,33014,745,507
Total operating expenses28,892,39816,744,97668,637,00739,184,320
Gain on sale of PREBOOST business   18,410,158
Operating (loss) income(21,823,775)(2,871,864)(38,551,024)14,843,883
Non-operating expenses:    
Interest expense(1,185,093)(1,287,525)(3,556,477)(3,728,259)
Change in fair value of derivative liabilities881,000(1,372,000)(557,000)(2,029,000)
Other income (expense), net69,895(34,540)135,897(170,841)
Total non-operating expenses(234,198)(2,694,065)(3,977,580)(5,928,100)
(Loss) income before income taxes(22,057,973)(5,565,929)(42,528,604)8,915,783
Income tax expense (benefit)137,603(2,873,063)224,808(2,773,071)
Net (loss) income$ (22,195,576)$ (2,692,866)$ (42,753,412)$ 11,688,854
Net (loss) income per basic common share outstanding$ (0.28)$ (0.03)$ (0.53)$ 0.16
Basic weighted average common shares outstanding80,088,43179,729,37080,054,59475,054,871
Net (loss) income per diluted common share outstanding$ (0.28)$ (0.03)$ (0.53)$ 0.14
Diluted weighted average common shares outstanding80,088,43179,729,37080,054,59482,807,156

VERU Balance Sheet

2022-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2022
Sep. 30, 2021
Current assets:  
Cash and cash equivalents$ 100,550,610$ 122,359,535
Accounts receivable, net8,302,7458,794,224
Notes receivable 5,000,000
Inventory, net7,722,5515,574,253
Prepaid research and development costs9,611,0669,174,586
Prepaid expenses and other current assets2,173,722850,889
Total current assets128,360,694151,753,487
Plant and equipment, net1,081,710592,603
Operating lease right-of-use assets4,970,311969,839
Deferred income taxes13,005,53313,024,550
Intangible assets, net3,995,2384,048,810
Goodwill6,878,9326,878,932
Other assets2,284,890878,502
Total assets160,577,308178,146,723
Current liabilities:  
Accounts payable6,936,3123,409,771
Accrued research and development costs10,721,3602,020,445
Accrued compensation4,016,7714,986,058
Accrued expenses and other current liabilities2,133,2861,615,922
Residual royalty agreement liability, short-term portion3,050,1353,237,211
Operating lease liability, short-term portion951,574497,903
Total current liabilities27,809,43815,767,310
Residual royalty agreement liability, long-term portion11,557,1909,397,136
Operating lease liability, long-term portion4,264,458609,921
Deferred income taxes63,42663,426
Other liabilities15,00014,986
Total liabilities43,709,51225,852,779
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, no shares issued and outstanding at June 30, 2022 and September 30, 2021
Common stock, par value $0.01 per share; 154,000,000 shares authorized, 82,311,689 and 82,153,452 shares issued and 80,127,985 and 79,969,748 shares outstanding at June 30, 2022 and September 30, 2021, respectively823,117821,535
Additional paid-in-capital248,984,393241,658,711
Accumulated other comprehensive loss(581,519)(581,519)
Accumulated deficit(124,551,590)(81,798,178)
Treasury stock, 2,183,704 shares, at cost(7,806,605)(7,806,605)
Total stockholders' equity116,867,796152,293,944
Total liabilities and stockholders' equity$ 160,577,308$ 178,146,723